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Venkatesh Y. Anjan, MD, Howard C. Herrmann, MDSEE PAGE 645W ith the advent and success of transcath-eter aortic valve replacement (TAVR),new emphasis is being placed on patient
selection to ensure successful outcomes after aortic
valve replacement (AVR). In this regard, clinicians
must appreciate that aortic stenosis (AS) is not a sim-
ple obstruction but involves a complex pathological
interaction among the left ventricle (LV), aortic valve
(AV), and peripheral vasculature (1). The most typical
form of AS is normal ﬂow high-gradient aortic stenosis
(NFHGAS), which is characterized by patients with a
normal left ventricular ejection fraction (EF), normal
ﬂow (left ventricular stroke volume index [LVSVI]
of >35 ml/m2), and a mean transvalvular gradient
of $40 mm Hg (Table 1). Recent studies have high-
lighted the importance of quantifying ﬂow in AS. A
low-ﬂow (LF) state (LVSVI #35 ml/m2) predicts worse
outcomes among patients undergoing AVR (2).
Furthermore, in patients with LF AS, there are 2 impor-
tant subtypes: classical low-ﬂow, low-gradient aortic
stenosis (LFLGAS) and paradoxical LFLGAS.
Patients with classical LFLGAS are characterized by
a low EF, low mean transvalvular gradient, and low
LVSVI (3). These signs can be difﬁcult to distinguish
from pseudoaortic stenosis, often requiring an
assessment of pump or contractile reserve and AS
severity with a higher ﬂow, using dobutamine stress
echocardiography. Recently, Hachicha et al. (4)
described the paradoxical LFLGAS subgroup that is
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(Table 1).
Patients with LFLGAS (both paradoxical and
classical) have a higher operative mortality than
NFHGAS patients (7–9). However, patients with
LFLGAS have survival rates that are still better with
AVR than with medical treatment (2,4,9). For this
reason, American Heart Association/American Col-
lege of Cardiology guidelines recommend that
symptomatic patients with classical LFLGAS undergo
AVR (10); European Society of Cardiology guidelines
recommend assessing ﬂow reserve prior to surgery,
but AVR is acceptable in either case (11). For symp-
tomatic patients with paradoxical LFLGAS, AVR is
recommended if valve obstruction is conﬁrmed as
the cause of symptoms (e.g., using computed to-
mography calcium scoring) (6).In this issue of the Journal, Clavel et al. (12) present
their single-center experience with 1,154 patients
with NFHGAS, paradoxical LFLGAS, and low EF AS
who underwent AVR. The majority of patients had
NFHGAS (54%); paradoxical LFLGAS and low EF AS
were present in 28% and 18% of patients, respec-
tively. Patients with paradoxical LFLGAS and low EF
AS had worse operative mortality than patients with
NFHGAS. In this analysis, paroxysmal LFLGAS and
low LVSVI were independent predictors of operative
mortality. Five-year mortality was highest among low
EF patients, and low EF was the only independent
predictor of 5-year survival.
This study provides new data for a large number
of patients with 3 major subtypes of AS undergoing
surgical AVR and their outcomes over a long follow-
up period. The study’s ﬁndings are consistent with
those of previous studies that demonstrate patients
with either paroxysmal LFLGAS or low EF have
worse operative mortality. Low EF was not a pre-
dictor of poor operative outcomes, which is likely
TABLE 1 Subtypes of Aortic Stenoses
Type of Aortic Stenosis
Mean
Gradient
(mm Hg)
LVEF
(%)
LV Stroke
Volume
Index (ml/m2)
Assessment
of Contractile
Reserve
Elevated
Computed
Tomography
AV Calcium
Score
Normal ﬂow high gradient $40 $50 >35  þ
Normal ﬂow and
gradient, low EF
$40 <50 >35  þ
Classical low ﬂow,
low gradient
<40 <50 #35 þ þ
Paradoxical low ﬂow,
low gradient
<40 $50 #35 þ/ þ
Pseudoaortic stenosis <40 < 50 #35  
AV ¼ aortic valve; EF ¼ ejection fraction; LV ¼ left ventricular.
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655related to the inclusion of the Parsonnet score in
the multivariate adjustment. It underscores a limi-
tation of operative risk scores, which may not
identify patients with paradoxical LFLGAS, or a
low LVSVI, who are at risk for adverse clinical
outcomes.
In the midterm analysis, it is not surprising that a
low EF was a predictor of poor long-term survival (8).
However, the low EF population Clavel et al. (12)
studied was a heterogeneous group. First, the fre-
quency of coronary artery disease, the myocardial
Duke jeopardy score, and the rate of concomitant
coronary artery bypass graft were all signiﬁcantly
higher in low EF patients. Concomitant coronary ar-
tery disease is common among low EF AS patients and
may explain the mortality differences among the
subgroups.
In addition, the low EF population (n ¼ 206) was
composed of patients with both normal (n ¼ 135)
and low LVSVI (n ¼ 71). There was a trend toward
increased perioperative mortality in patients with
low LVSVI (OR: 1.81; 95% conﬁdence interval: 0.48
to 6.81; p ¼ 0.36). These 71 patients likely repre-
sented the same phenotype as classic LFLGAS. It is
unclear how many patients had a normal LVSVI
and a high gradient despite a low EF. Previous
studies have demonstrated the relationship be-
tween low preoperative transvalvular gradient and
perioperative mortality (13). Classifying AS patients
solely by EF may explain why LVSVI was not
a predictor of long-term survival as previously
reported (2).
What information do clinicians still need to
manage patients with atypical forms of AS? First,
further investigation is required to determine which
features of LFLGAS predict improvement in EF,
LVSVI, and survival after AVR. Achieving this goal
may require referring patients to surgery earlier and
evaluating measurements from the peripheral vas-
culature. For example, many asymptomatic LFLGAS
patients exhibit increased global LV load resultingin decreased myocardial systolic function and in-
creased valvuloarterial impedance, which represent
possible parameters to be used in clinical decision
making (14). It is apparent that LVSVI is crucial for
risk-stratifying patients undergoing AVR; however, it
may not be a sufﬁcient determinant for proceeding
with AVR, because both symptomatic classic and
paradoxical LFLGAS patients have improved out-
comes with AVR. Whether TAVR is a better option
than surgical AVR as suggested in some observational
studies requires further evaluation. Finally, it is clear
that severe AS deﬁned solely by aortic valve area is
insufﬁcient as a marker for short- and long-term
prognoses in patients undergoing AVR. A thorough
evaluation of EF, contractility, ﬂow, peripheral
vasculature, and their interaction is required to fully
understand the disease process, assess operative risk,
and predict long-term survival.
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